Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0S0HA
|
||||
| Former ID |
DIB015019
|
||||
| Drug Name |
O6-Benzylguanine alkylade
|
||||
| Synonyms |
KRX-0402; O6-Benzylguanine; O6-Benzylguanine (BG)
|
||||
| Company |
Wiley-Liss; Keryx Biopharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
Nc1nc(OCc2ccccc2)c3nc[nH]c3n1
|
||||
| InChI |
1S/C12H11N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H3,13,14,15,16,17)
|
||||
| InChIKey |
KRWMERLEINMZFT-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Methylated-DNA--protein-cysteine methyltransferase | Target Info | Modulator | [527774], [529958] | |
| WikiPathways | DNA Damage Reversal | ||||
| References | |||||
| Ref 527774 | Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005 Oct 1;23(28):7178-87. | ||||
| Ref 529958 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10;27(8):1262-7. | ||||
| Ref 527774 | Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005 Oct 1;23(28):7178-87. | ||||
| Ref 529958 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10;27(8):1262-7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.